BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim BH, Park JW. Epidemiology of liver cancer in South Korea. Clin Mol Hepatol 2018;24:1-9. [PMID: 29249129 DOI: 10.3350/cmh.2017.0112] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 15.8] [Reference Citation Analysis]
Number Citing Articles
1 Kweon SS. Updates on Cancer Epidemiology in Korea, 2018. Chonnam Med J 2018;54:90-100. [PMID: 29854674 DOI: 10.4068/cmj.2018.54.2.90] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 11.3] [Reference Citation Analysis]
2 Barry A, Apisarnthanarax S, O'Kane GM, Sapisochin G, Beecroft R, Salem R, Yoon SM, Lim YS, Bridgewater J, Davidson B, Scorsetti M, Solbiati L, Diehl A, Schuffenegger PM, Sham JG, Cavallucci D, Galvin Z, Dawson LA, Hawkins MA. Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. Lancet Gastroenterol Hepatol. 2020;5:765-775. [PMID: 32511951 DOI: 10.1016/s2468-1253(20)30182-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
3 Oh S, Choi K, Kim KM, Jung J. Sex-dependent effects of estrogen pellets in human liver cancer xenograft models. Toxicol Res 2020;36:109-14. [PMID: 32257922 DOI: 10.1007/s43188-019-00020-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Choi WM, Choi J, Lee D, Shim JH, Lim YS, Lee HC, Chung YH, Lee YS, Park SR, Ryu MH, Ryoo BY, Lee SJ, Kim KM. Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma. Hepatol Commun. 2020;4:1073-1086. [PMID: 32626838 DOI: 10.1002/hep4.1523] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
5 Choi NR, Kim JY, Hong JH, Hur MH, Cho H, Park MK, Kim J, Lee YB, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterol 2022;22:135. [PMID: 35337274 DOI: 10.1186/s12876-022-02210-3] [Reference Citation Analysis]
6 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 21.3] [Reference Citation Analysis]
7 Kim BK, Kim DY, Han KH, Seong J. Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study. PLoS One 2019;14:e0223678. [PMID: 31622424 DOI: 10.1371/journal.pone.0223678] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Lee HW, Cho KJ, Park JY. Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest? Immune Netw 2020;20:e11. [PMID: 32158599 DOI: 10.4110/in.2020.20.e11] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
9 Choi WM, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Yoo C, Park SR, Ryu MH, Ryoo BY, Choi J. Effectiveness and Safety of Nivolumab in Child-Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study. Cancers (Basel) 2020;12:E1968. [PMID: 32698355 DOI: 10.3390/cancers12071968] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
10 Sinn DH, Kang D, Kang M, Paik SW, Guallar E, Cho J, Gwak GY. Late presentation of hepatitis B among patients with newly diagnosed hepatocellular carcinoma: a national cohort study. BMC Cancer 2019;19:286. [PMID: 30922251 DOI: 10.1186/s12885-019-5508-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy. Liver Int. 2019;39:1624-1630. [PMID: 31050379 DOI: 10.1111/liv.14129] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
12 Petrick JL, Florio AA, Znaor A, Ruggieri D, Laversanne M, Alvarez CS, Ferlay J, Valery PC, Bray F, McGlynn KA. International trends in hepatocellular carcinoma incidence, 1978-2012. Int J Cancer. 2020;147:317-330. [PMID: 31597196 DOI: 10.1002/ijc.32723] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 11.3] [Reference Citation Analysis]
13 Park JW, Kim YJ, Kim DY, Bae SH, Paik SW, Lee YJ, Kim HY, Lee HC, Han SY, Cheong JY, Kwon OS, Yeon JE, Kim BH, Hwang J. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial. J Hepatol. 2019;70:684-691. [PMID: 30529387 DOI: 10.1016/j.jhep.2018.11.029] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 12.8] [Reference Citation Analysis]
14 Yoon SM, Kim SY, Lim YS, Kim KM, Shim JH, Lee D, An J, Jung J, Kim JH, Lee HC. Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial. Clin Mol Hepatol 2020;26:506-15. [PMID: 32646200 DOI: 10.3350/cmh.2020.0038] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
15 Suh JK, Lee J, Lee JH, Shin S, Tchoe HJ, Kwon JW. Risk factors for developing liver cancer in people with and without liver disease. PLoS One 2018;13:e0206374. [PMID: 30372481 DOI: 10.1371/journal.pone.0206374] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
16 Kim DJ, Yoo JW, Chang JW, Yamashita T, Park EC, Han KT, Kim SJ, Kim SJ. Does low income effects 5-year mortality of hepatocellular carcinoma patients? Int J Equity Health 2021;20:151. [PMID: 34465351 DOI: 10.1186/s12939-021-01498-z] [Reference Citation Analysis]
17 Hwang S, Park YM, Han KD, Yun JS, Ko SH, Ahn YB, Han JH. Associations of general obesity and central obesity with the risk of hepatocellular carcinoma in a Korean population: A national population-based cohort study. Int J Cancer 2021;148:1144-54. [PMID: 32955731 DOI: 10.1002/ijc.33305] [Reference Citation Analysis]
18 Cho HJ, Baek GO, Yoon MG, Ahn HR, Son JA, Kim SS, Cheong JY, Eun JW. Overexpressed Proteins in HCC Cell-Derived Exosomes, CCT8, and Cofilin-1 Are Potential Biomarkers for Patients with HCC. Diagnostics (Basel) 2021;11:1221. [PMID: 34359304 DOI: 10.3390/diagnostics11071221] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Sinn DH, Choi GS, Park HC, Kim JM, Kim H, Song KD, Kang TW, Lee MW, Rhim H, Hyun D, Cho SK, Shin SW, Jeong WK, Kim SH, Yu JI, Ha SY, Lee SJ, Lim HY, Kim K, Ahn JH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Joh JW, Lim HK, Paik SW. Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. PLoS One. 2019;14:e0210730. [PMID: 30640924 DOI: 10.1371/journal.pone.0210730] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
20 Lee S, Jung J, Park JH, Kim SY, Choi J, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Park HH, Kim JH, Yoon SM. Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients. BMC Cancer 2022;22:175. [PMID: 35172769 DOI: 10.1186/s12885-022-09263-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Wang J, Li X. Impact of statin use on the risk and prognosis of hepatocellular carcinoma: a meta-analysis. Eur J Gastroenterol Hepatol 2021;33:1603-9. [PMID: 33405428 DOI: 10.1097/MEG.0000000000002040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Cho HJ, Cheong JY. Role of Immune Cells in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. Int J Mol Sci 2021;22:8011. [PMID: 34360777 DOI: 10.3390/ijms22158011] [Reference Citation Analysis]
23 Kim JH, Choe WH, Kwon SY, Yoo BC. Prognosis of Spontaneous Bacterial Peritonitis in Hepatocellular Carcinoma Patients. J Korean Med Sci 2018;33:e335. [PMID: 30584413 DOI: 10.3346/jkms.2018.33.e335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Choi YB, Lee NH, Yi ES, Kim YJ, Koo HH. Changes in hepatitis B antibody status after chemotherapy in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2019;66:e27904. [PMID: 31448550 DOI: 10.1002/pbc.27904] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Lu W, Zheng F, Li Z, Zhou R, Deng L, Xiao W, Chen W, Zhao R, Chen Y, Tan Y, Li Z, Liu L, Tan D, Liu N. Association Between Environmental and Socioeconomic Risk Factors and Hepatocellular Carcinoma: A Meta-Analysis. Front Public Health 2022;10:741490. [DOI: 10.3389/fpubh.2022.741490] [Reference Citation Analysis]
26 Wu Y, Liu Y, Mao P, Ma G, Xue W, Tang W. Structural characterization and anti-liver cancer activity of two Cu(II) coordination polymers. Inorganic and Nano-Metal Chemistry. [DOI: 10.1080/24701556.2021.1897142] [Reference Citation Analysis]
27 Shin J, Yu JH, Jin YJ, Suh YJ, Kim DH, Byun S, Lee JW. Effective therapeutic options for elderly patients with hepatocellular carcinoma: A nationwide cohort study. Medicine (Baltimore) 2019;98:e16150. [PMID: 31348228 DOI: 10.1097/MD.0000000000016150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Tran NH. Shifting Epidemiology of Hepatocellular Carcinoma in Far Eastern and Southeast Asian Patients: Explanations and Implications. Curr Oncol Rep. [DOI: 10.1007/s11912-021-01160-5] [Reference Citation Analysis]
29 Schepis TS, Ford JA, Wastila L, McCabe SE. Opioid-involved prescription drug misuse and poly-prescription drug misuse in U.S. older adults. Aging Ment Health 2020;:1-9. [PMID: 33131295 DOI: 10.1080/13607863.2020.1839859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Park S, Rim CH, Jung YK, Yoon WS. Therapeutic Decision Making in Hepatocellular Carcinoma According to Age and Child-Pugh Class: A Nationwide Cohort Analysis in South Korea. Can J Gastroenterol Hepatol 2021;2021:6640121. [PMID: 33505941 DOI: 10.1155/2021/6640121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Chon HY, Lee JS, Lee HW, Chun HS, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B. Hepatology Research 2021;51:406-16. [DOI: 10.1111/hepr.13600] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Kim GA, Kim HI, Chang S, An J, Lee D, Lee HC, Han S, Shim JH. A Prospective Evaluation of the Reliability and Utility of Quality of Life Measures in Patients With Hepatocellular Carcinoma. Am J Clin Oncol 2019;42:555-63. [PMID: 31135382 DOI: 10.1097/COC.0000000000000555] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
33 Lee HW, Kim SU, Park JY, Baatarkhuu O, Kim DY, Ahn SH, Han KH, Kim BK. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals. Clin Transl Gastroenterol 2019;10:e00036. [PMID: 31107725 DOI: 10.14309/ctg.0000000000000036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
34 Lee JS, Lee HA, Jeon MY, Lim TS, Kim BK, Park JY, Kim DY, Ahn SH, Um SH, Han K, Seo YS, Kim SU. Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization. European Journal of Gastroenterology & Hepatology 2020;32:739-47. [DOI: 10.1097/meg.0000000000001585] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Lee HL, Jang JW, Lee SW, Yoo SH, Kwon JH, Nam SW, Bae SH, Choi JY, Han NI, Yoon SK. Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization. Sci Rep 2019;9:3260. [PMID: 30824840 DOI: 10.1038/s41598-019-40078-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
36 D'silva M, Cho JY, Han H, Yoon Y, Lee HW, Lee JS, Lee B, Kim M. Long-term surgical outcomes of Non alcoholic fatty liver disease associated hepatocellular carcinoma. Surgical Oncology 2022;41:101730. [DOI: 10.1016/j.suronc.2022.101730] [Reference Citation Analysis]
37 Choi SI, Cho Y, Ki M, Kim BH, Lee IJ, Kim TH, Kim SH, Koh YH, Kim HB, Hong EK, Kim CM, Park JW. Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts. PLoS One 2022;17:e0265668. [PMID: 35324973 DOI: 10.1371/journal.pone.0265668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Hur MH, Lee JH, Kim JY, Hong JH, Park MK, Cho HJ, Choi NR, Kim J, Kim MA, Nam JY, Lee YB, Cho EJ, Yu SJ, Kim YJ, Lee DH, Lee JM, Hong SK, Yi NJ, Lee KW, Suh KS, Yoon JH. Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:6009. [PMID: 34885118 DOI: 10.3390/cancers13236009] [Reference Citation Analysis]
39 Park S, Jung J, Cho B, Kim SY, Yun SC, Lim YS, Lee HC, Park J, Park JH, Kim JH, Yoon SM. Clinical outcomes of stereotactic body radiation therapy for small hepatocellular carcinoma. J Gastroenterol Hepatol 2020;35:1953-9. [PMID: 32052884 DOI: 10.1111/jgh.15011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
40 Kim J, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. Clin Mol Hepatol 2020;26:516-28. [PMID: 32911589 DOI: 10.3350/cmh.2020.0016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
41 Kim TH, Chang JM, Um SH, Jee H, Lee YR, Lee HA, Yim SY, Han NY, Lee JM, Choi HS, Kim ES, Yu YD, Keum B, Kim MJ, An H, Park BJ, Seo YS, Kim DS, Yim HJ, Cho SB, Jeen YT, Lee HS, Chun HJ, Kim YH, Kim CD. Comparison of 2 curative treatment options for very early hepatocellular carcinoma: Efficacy, recurrence pattern, and retreatment. Medicine (Baltimore) 2019;98:e16279. [PMID: 31261600 DOI: 10.1097/MD.0000000000016279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
42 Kim YA, Kang D, Moon H, Sinn D, Kang M, Woo SM, Chang YJ, Park B, Kong SY, Guallar E, Shin SY, Gwak G, Back JH, Lee ES, Cho J. Survival in untreated hepatocellular carcinoma: A national cohort study. PLoS One 2021;16:e0246143. [PMID: 33539397 DOI: 10.1371/journal.pone.0246143] [Reference Citation Analysis]
43 Schepis TS, Klare DL, Ford JA, McCabe SE. Prescription Drug Misuse: Taking a Lifespan Perspective. Subst Abuse 2020;14:1178221820909352. [PMID: 32214819 DOI: 10.1177/1178221820909352] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
44 Lee YS, Jung YK, Kim JH, Cho SB, Kim DY, Kim MY, Kim HJ, Seo YS, Yoon KT, Hong YM, Lee JH, Lee HW, Yim HJ, Jang BK, Jang ES, Jang JY, Hwang SY. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study. Eur J Cancer 2020;140:19-27. [PMID: 33039810 DOI: 10.1016/j.ejca.2020.09.012] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Sinn DH, Kang D, Cho SJ, Paik SW, Guallar E, Cho J, Gwak GY. Risk of hepatocellular carcinoma in individuals without traditional risk factors: development and validation of a novel risk score. Int J Epidemiol 2020;49:1562-71. [PMID: 32725117 DOI: 10.1093/ije/dyaa089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
46 Lee JH, Kim BK, Park SY, Tak WY, Park JY, Kim DY, Ahn SH, Sinn DH, Kim SU. The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma. Eur J Intern Med 2021;89:48-55. [PMID: 33810942 DOI: 10.1016/j.ejim.2021.02.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
47 Chang JI, Sinn DH, Cho H, Kim S, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Clinical Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels. Dig Dis Sci 2021. [PMID: 34800218 DOI: 10.1007/s10620-021-07312-8] [Reference Citation Analysis]
48 Rho SY, Lee HW, Kim DY, Kim KS. Current Status of Therapeutic Choice and Feasibility for Patients with Hepatocellular Carcinoma Aged ≥ 70 Years: A Nationwide Cancer Registry Analysis. J Hepatocell Carcinoma 2021;8:321-32. [PMID: 33959557 DOI: 10.2147/JHC.S306507] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Xu J, Yang X, Zhou Q, Zhuang J, Han S. Biological significance of piRNA in liver cancer: a review. Biomarkers 2020;25:436-40. [PMID: 32662667 DOI: 10.1080/1354750X.2020.1794041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
50 Zhang Y, Cao N, Gao J, Liang J, Liang Y, Xie Y, Zhou S, Tang X. ASIC1a stimulates the resistance of human hepatocellular carcinoma by promoting EMT via the AKT/GSK3β/Snail pathway driven by TGFβ/Smad signals. J Cellular Molecular Medi. [DOI: 10.1111/jcmm.17288] [Reference Citation Analysis]
51 Seol HS, Akiyama Y, Lee SE, Shimada S, Jang SJ. Loss of miR-100 and miR-125b results in cancer stem cell properties through IGF2 upregulation in hepatocellular carcinoma. Sci Rep 2020;10:21412. [PMID: 33293585 DOI: 10.1038/s41598-020-77960-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
52 Ko SY, Choe WH. Potential prognostic factors for solitary hepatocellular carcinoma ≤ 5 cm after transarterial chemoembolization. Korean J Intern Med 2019;34:1210-1. [PMID: 31671925 DOI: 10.3904/kjim.2019.344] [Reference Citation Analysis]
53 Cho YY, Yu SJ, Lee HW, Kim DY, Kang W, Paik YH, Sung PS, Bae SH, Park SC, Doh YS, Kim KM, Jang ES, Kim IH, Kim W, Kim YJ. Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study. J Hepatocell Carcinoma 2021;8:613-23. [PMID: 34169044 DOI: 10.2147/JHC.S304439] [Reference Citation Analysis]
54 Chon YE, Park H, Hyun HK, Ha Y, Kim MN, Kim BK, Lee JH, Kim SU, Kim DY, Ahn SH, Hwang SG, Han KH, Rim KS, Park JY. Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Cancers (Basel) 2019;11:E509. [PMID: 30974843 DOI: 10.3390/cancers11040509] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
55 Chang Y, Cho Y, Lee JH, Lee YB, Cho EJ, Yu SJ, Sinn DH, Kim BH, Kim SH, Yi NJ, Lee KW, Kim JM, Park JW, Kim YJ, Yoon JH, Joh JW, Suh KS. Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study. Cancers (Basel) 2019;11:E1295. [PMID: 31484287 DOI: 10.3390/cancers11091295] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
56 Yu X, Wang Y, Tao S, Sun S. Geniposide plays anti-tumor effects by down-regulation of microRNA-224 in HepG2 and Huh7 cell lines. Exp Mol Pathol 2020;112:104349. [PMID: 31778668 DOI: 10.1016/j.yexmp.2019.104349] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
57 Shim JH. Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease? Clin Mol Hepatol 2020;26:183-4. [PMID: 32160729 DOI: 10.3350/cmh.2020.0042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
58 Chon YE, Jeong SW, Jun DW. Hepatocellular carcinoma statistics in South Korea. Clin Mol Hepatol 2021;27:512-4. [PMID: 34153973 DOI: 10.3350/cmh.2021.0171] [Reference Citation Analysis]
59 Sinn DH, Kang D, Guallar E, Hong YS, Cho J, Gwak G. Modest alcohol intake and mortality in individuals with elevated alanine aminotransferase levels: a nationwide cohort study. BMC Med 2022;20. [DOI: 10.1186/s12916-021-02215-x] [Reference Citation Analysis]
60 Hong JH, Lee K, Kim J, Ahn KM. Prognosis of hepatocellular carcinoma metastasizing to the oral cavity. Maxillofac Plast Reconstr Surg 2021;43:9. [PMID: 33689049 DOI: 10.1186/s40902-021-00294-7] [Reference Citation Analysis]
61 Han S, Lee HW, Park JY, Kim SU, Kim DY, Ahn SH, Han KH, Seong J, Won JY, Han DH, Kim BK. Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion. J Hepatocell Carcinoma 2020;7:403-12. [PMID: 33365287 DOI: 10.2147/JHC.S276528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Shen Q, Xia Y, Yang L, Wang B, Peng J, Tang M. Midazolam Suppresses Hepatocellular Carcinoma Cell Metastasis and Enhances Apoptosis by Elevating miR-217. Computational and Mathematical Methods in Medicine 2022;2022:1-9. [DOI: 10.1155/2022/2813521] [Reference Citation Analysis]
63 Lim J, Kim KW, Ko Y, Jang IY, Lee YS, Chung YH, Lee HC, Lim YS, Kim KM, Shim JH, Choi J, Lee D. The role of muscle depletion and visceral adiposity in HCC patients aged 65 and over undergoing TACE. BMC Cancer 2021;21:1164. [PMID: 34715813 DOI: 10.1186/s12885-021-08905-2] [Reference Citation Analysis]
64 Zhang C, Wang LL, Cao CY, Li N, Talukder M, Li JL. Selenium mitigates cadmium-induced crosstalk between autophagy and endoplasmic reticulum stress via regulating calcium homeostasis in avian leghorn male hepatoma (LMH) cells. Environ Pollut 2020;265:114613. [PMID: 32504893 DOI: 10.1016/j.envpol.2020.114613] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
65 Kim S, Choi Y, Kwak DW, Lee HS, Hur WJ, Baek YH, Lee SW. Prognostic factors in hepatocellular carcinoma patients with bone metastases. Radiat Oncol J 2019;37:207-14. [PMID: 31591869 DOI: 10.3857/roj.2019.00136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
66 Chon HY, Ahn SH, Kim YJ, Yoon JH, Lee JH, Sinn DH, Kim SU. Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients. Hepatol Int 2021;15:1328-36. [PMID: 34799838 DOI: 10.1007/s12072-021-10262-y] [Reference Citation Analysis]
67 Zhang CH, Cheng Y, Zhang S, Fan J, Gao Q. Changing Epidemiology of Hepatocellular Carcinoma in Asia. Liver Int 2022. [PMID: 35319165 DOI: 10.1111/liv.15251] [Reference Citation Analysis]
68 Lee HW. [Long Term Efficacy of Antiviral Therapy: Mortality and Incidence of Hepatocellular Carcinoma]. Korean J Gastroenterol 2019;74:251-7. [PMID: 31765553 DOI: 10.4166/kjg.2019.74.5.251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Chon HY, Lee JS, Lee HW, Chun HS, Kim BK, Tak WY, Park JY, Kweon YO, Kim DY, Ahn SH, Jang SY, Park SY, Kim SU. Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00604-2. [PMID: 34091048 DOI: 10.1016/j.cgh.2021.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
70 An C, Choi JW, Lee HS, Lim H, Ryu SJ, Chang JH, Oh HC. Prediction of the risk of developing hepatocellular carcinoma in health screening examinees: a Korean cohort study. BMC Cancer 2021;21:755. [PMID: 34187409 DOI: 10.1186/s12885-021-08498-w] [Reference Citation Analysis]
71 Cho YY, Yu SJ, Yoo JJ, Lee M, Lee DH, Cho Y, Yoon KW, Cho EJ, Lee JH, Kim YJ, Yoon JH. The Model to Estimate Survival in Ambulatory Hepatocellular Carcinoma Patients Aids in the Decision for TACE Retreatment. J Clin Gastroenterol 2020;54:370-7. [PMID: 30439763 DOI: 10.1097/MCG.0000000000001148] [Reference Citation Analysis]
72 Chon HY, Lee HA, Suh SJ, Lee JI, Kim BS, Kim IH, Lee CH, Jang BK, Lee HW, Hwang JS, Lee CH, Lee JW, Yu JH, Seo YS, Yim HJ, Kim SU; Korean Transient Elastography Study Group. Addition of liver stiffness enhances the predictive accuracy of the PAGE-B model for hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2021;53:919-27. [PMID: 33465253 DOI: 10.1111/apt.16267] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Kwon Y, Kim JR, Park YM, Choi BK, Kim C, Young Kim H, Yoon M. Predicting survival time of Korean hepatocellular carcinoma patients using the Cox proportional hazards model: a retrospective study based on big data analysis. Eur J Gastroenterol Hepatol 2021;33:1001-8. [PMID: 33470702 DOI: 10.1097/MEG.0000000000002058] [Reference Citation Analysis]
74 Tobari M, Hashimoto E. Characteristic Features of Nonalcoholic Fatty Liver Disease in Japan with a Focus on the Roles of Age, Sex and Body Mass Index. Gut Liver 2020;14:537-45. [PMID: 31887811 DOI: 10.5009/gnl19236] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
75 Yun BY, Lee HW, Min IK, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation. Cancers (Basel). 2020;12. [PMID: 32899584 DOI: 10.3390/cancers12092527] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
76 Kim MJ, Paramanantham A, Lee WS, Yun JW, Chang SH, Kim DC, Park HS, Choi YH, Kim GS, Ryu CH, Shin SC, Hong SC. Anthocyanins Derived from Vitis coignetiae Pulliat Contributes Anti-Cancer Effects by Suppressing NF-κB Pathways in Hep3B Human Hepatocellular Carcinoma Cells and In Vivo. Molecules 2020;25:E5445. [PMID: 33233701 DOI: 10.3390/molecules25225445] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
77 Yim SY, Kim JH. The epidemiology of hepatitis B virus infection in Korea. Korean J Intern Med 2019;34:945-53. [PMID: 30919608 DOI: 10.3904/kjim.2019.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
78 Seo JY, Shin DW, Yu SJ, Jung JH, Han K, Cho IY, Kim SY, Choi KS, Park JH, Park JH, Kawachi I. Disparities in Liver Cancer Surveillance Among People With Disabilities: A National Database Study in Korea. J Clin Gastroenterol 2021;55:439-48. [PMID: 32889960 DOI: 10.1097/MCG.0000000000001405] [Reference Citation Analysis]
79 Kim CG, Lee HW, Choi HJ, Lee JI, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim HS, Kim KH, Choi SJ, Kim Y, Lee KS, Kim GM, Kim MD, Won JY, Lee DY, Kim BK. Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. Cancer Med. 2019;8:5023-5032. [PMID: 31290618 DOI: 10.1002/cam4.2417] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
80 Sinn DH, Kang D, Guallar E, Chang Y, Ryu S, Zhao D, Hong YS, Cho J, Gwak GY. Alcohol Intake and Mortality in Patients With Chronic Viral Hepatitis: A Nationwide Cohort Study. Am J Gastroenterol 2021;116:329-35. [PMID: 33038136 DOI: 10.14309/ajg.0000000000000966] [Reference Citation Analysis]
81 Lee HW, Park SY, Lee M, Lee EJ, Lee J, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia. Liver Int. 2020;40:1736-1743. [PMID: 32239602 DOI: 10.1111/liv.14451] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
82 Jekarl DW, Lee S, Kwon JH, Nam SW, Kim M, Kim Y, Jang JW. Complex interaction networks of cytokines after transarterial chemotherapy in patients with hepatocellular carcinoma. PLoS One 2019;14:e0224318. [PMID: 31751357 DOI: 10.1371/journal.pone.0224318] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
83 Hu W, Shi Y, Han T, Liu C, Cao X, Shi G, Zhu W. A Panel of E2F Target Gene Signature Predicting the Prognosis of Hepatocellular Carcinoma. Front Genet 2022;13:879299. [DOI: 10.3389/fgene.2022.879299] [Reference Citation Analysis]
84 Kim SU, Chon YE, Seo YS, Lee HW, Lee HA, Kim MN, Min IK, Park JY, Kim DY, Ahn SH, Tak WY, Kim BK, Park SY. A multi‐centre study of trends in hepatitis B virus‐related hepatocellular carcinoma risk over time during long‐term entecavir therapy. J Viral Hepat 2020;27:1352-8. [DOI: 10.1111/jvh.13384] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
85 Tateishi R, Koike K. Changing etiology of hepatocellular carcinoma. J Gastroenterol 2020;55:125-6. [PMID: 31473829 DOI: 10.1007/s00535-019-01622-5] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
86 Kim YJ, Jung J, Joo JH, Kim SY, Kim JH, Lim YS, Lee HC, Kim JH, Yoon SM. Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C. Radiother Oncol 2019;141:95-100. [PMID: 31506181 DOI: 10.1016/j.radonc.2019.08.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
87 Kim TS, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia. J Gastroenterol Hepatol 2019;34:2028-35. [PMID: 31157456 DOI: 10.1111/jgh.14750] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
88 Park HK, Lee SS, Im CB, Im C, Cha RR, Kim WS, Cho HC, Lee JM, Kim HJ, Kim TH, Jung WT, Lee OJ. Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma. BMC Cancer 2019;19:822. [PMID: 31429755 DOI: 10.1186/s12885-019-6040-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
89 Lee JS, Cho IR, Lee HW, Jeon MY, Lim TS, Baatarkhuu O, Kim DY, Han KH, Park JY. Conditional Survival Estimates Improve Over Time for Patients with Hepatocellular Carcinoma: An Analysis for Nationwide Korea Cancer Registry Database. Cancer Res Treat 2019;51:1347-56. [PMID: 30744320 DOI: 10.4143/crt.2018.477] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]